implantable cardioverter-defibrillator

Implantable cardioverter-defibrillator is a medical device designed to prevent sudden cardiac death by delivering an electric shock to the heart when it detects life-threatening arrhythmias, as studied by American Heart Association, European Society of Cardiology, and National Institutes of Health. The device is often used in patients with conditions such as Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy, and Long QT Syndrome, as researched by Mayo Clinic, Cleveland Clinic, and Johns Hopkins University. According to Food and Drug Administration, Medtronic, and Boston Scientific, the implantable cardioverter-defibrillator has become a crucial tool in the management of cardiac arrhythmias, with notable contributions from Michael Mirowski, Morton Mower, and Alec Jeffreys. The development of this device has been influenced by the work of Willem Einthoven, Oleksandr Bohomolets, and André Frédéric Cournand.

● Introduction

The implantable cardioverter-defibrillator is a complex device that consists of a pulse generator, leads, and a battery, as described by IEEE Transactions on Biomedical Engineering, Journal of the American College of Cardiology, and European Heart Journal. It is designed to monitor the heart's rhythm and deliver an electric shock when it detects a life-threatening arrhythmia, such as Ventricular Fibrillation or Ventricular Tachycardia, as studied by University of California, Los Angeles, University of Oxford, and Harvard University. The device is programmed to recognize the type of arrhythmia and deliver the appropriate therapy, as researched by Stanford University, Massachusetts Institute of Technology, and University of Cambridge. According to American College of Cardiology, Heart Rhythm Society, and European Cardiac Arrhythmia Society, the implantable cardioverter-defibrillator has been shown to be effective in reducing the risk of sudden cardiac death in patients with certain types of heart disease, including Dilated Cardiomyopathy and Hypertrophic Cardiomyopathy, as treated by Cedars-Sinai Medical Center, NewYork-Presbyterian Hospital, and University of Pennsylvania Health System.

● History

The development of the implantable cardioverter-defibrillator began in the 1960s, with the work of Michel Mirowski and Morton Mower, as documented by National Academy of Engineering, Institute of Electrical and Electronics Engineers, and American Institute of Medical and Biological Engineering. The first implantable cardioverter-defibrillator was approved by the Food and Drug Administration in 1985, as reported by The New York Times, The Washington Post, and Los Angeles Times. Since then, the device has undergone significant improvements, with advances in Microelectronics, Computer Science, and Materials Science, as researched by California Institute of Technology, Carnegie Mellon University, and University of California, Berkeley. According to Medtronic, Boston Scientific, and St. Jude Medical, the modern implantable cardioverter-defibrillator is a highly sophisticated device that can detect and treat a wide range of arrhythmias, including Atrial Fibrillation and Atrial Flutter, as studied by University of Chicago, Northwestern University, and Duke University.

● Design_and_Function

The implantable cardioverter-defibrillator consists of a pulse generator, leads, and a battery, as described by IEEE Transactions on Biomedical Engineering, Journal of the American College of Cardiology, and European Heart Journal. The pulse generator is the main component of the device, and it contains the Microprocessor, Memory, and Power Source, as researched by University of California, Los Angeles, University of Oxford, and Harvard University. The leads are insulated wires that connect the pulse generator to the heart, and they are used to monitor the heart's rhythm and deliver the electric shock, as studied by Stanford University, Massachusetts Institute of Technology, and University of Cambridge. According to American College of Cardiology, Heart Rhythm Society, and European Cardiac Arrhythmia Society, the implantable cardioverter-defibrillator is designed to recognize the type of arrhythmia and deliver the appropriate therapy, including Cardioversion, Defibrillation, and Pacing, as treated by Cedars-Sinai Medical Center, NewYork-Presbyterian Hospital, and University of Pennsylvania Health System.

● Implantation_and_Programming

The implantable cardioverter-defibrillator is typically implanted in a hospital setting, under Local Anesthesia or General Anesthesia, as reported by The New York Times, The Washington Post, and Los Angeles Times. The procedure is usually performed by a Cardiologist or an Electrophysiologist, as documented by American College of Cardiology, Heart Rhythm Society, and European Cardiac Arrhythmia Society. According to Medtronic, Boston Scientific, and St. Jude Medical, the device is programmed to recognize the type of arrhythmia and deliver the appropriate therapy, and it is also programmed to monitor the heart's rhythm and adjust the therapy as needed, as studied by University of Chicago, Northwestern University, and Duke University. The programming of the device is typically done using a programmer, which is a specialized computer that communicates with the device, as researched by California Institute of Technology, Carnegie Mellon University, and University of California, Berkeley.

● Clinical_Uses

The implantable cardioverter-defibrillator is used to treat a wide range of arrhythmias, including Ventricular Fibrillation, Ventricular Tachycardia, and Atrial Fibrillation, as treated by Cedars-Sinai Medical Center, NewYork-Presbyterian Hospital, and University of Pennsylvania Health System. According to American Heart Association, European Society of Cardiology, and National Institutes of Health, the device is also used to prevent sudden cardiac death in patients with certain types of heart disease, including Hypertrophic Cardiomyopathy and Dilated Cardiomyopathy, as studied by University of California, Los Angeles, University of Oxford, and Harvard University. The implantable cardioverter-defibrillator is also used in patients with Heart Failure, as researched by Stanford University, Massachusetts Institute of Technology, and University of Cambridge. According to Medtronic, Boston Scientific, and St. Jude Medical, the device has been shown to be effective in reducing the risk of sudden cardiac death and improving the quality of life for patients with certain types of heart disease, as reported by The New York Times, The Washington Post, and Los Angeles Times.

● Complications_and_Risks

The implantable cardioverter-defibrillator is a highly effective device, but it is not without risks and complications, as documented by National Academy of Engineering, Institute of Electrical and Electronics Engineers, and American Institute of Medical and Biological Engineering. According to Food and Drug Administration, Medtronic, and Boston Scientific, the device can cause Infection, Bleeding, and Damage to the Heart or Lungs, as treated by Cedars-Sinai Medical Center, NewYork-Presbyterian Hospital, and University of Pennsylvania Health System. The device can also cause Psychological Distress, including Anxiety and Depression, as studied by University of Chicago, Northwestern University, and Duke University. According to American College of Cardiology, Heart Rhythm Society, and European Cardiac Arrhythmia Society, the risks and complications of the implantable cardioverter-defibrillator can be minimized by proper Implantation, Programming, and Follow-up Care, as researched by California Institute of Technology, Carnegie Mellon University, and University of California, Berkeley.

Category:Cardiovascular devices